

Embarc Benefit Protection™ Policy

POLICY: Hemophilia – Hemgenix® (etranacogene dezaparvovec-drlb intravenous infusion – CSL Behring and uniQure)

EFFECTIVE DATE: January 23, 2023

VERSION: 1.0.2023

OVERVIEW

Hemgenix, an adeno-associated virus vector-based gene therapy, is indicated for the treatment of adults with hemophilia B (congenital Factor IX deficiency) who: 1) currently use Factor IX prophylaxis therapy; or 2) have current or historical life-threatening hemorrhage; or 3) have repeated, serious spontaneous bleeding episodes.¹

Disease Overview

Hemophilia B is a genetic bleeding disorder caused by missing or insufficient levels of blood Factor IX, a protein required to produce blood clots to halt bleeding.²⁻⁵ The condition is a rare X-linked bleeding disorder that mainly impacts males. Hemophilia B is four times less common than hemophilia A, which is caused by a relative lack of blood Factor VIII. Approximately 30,000 individual are living with hemophilia in the US and hemophilia B accounts for around 15% to 20% of hemophilia cases, or around 6,000 patients. Symptoms patients may experience include heavy or prolonged bleeding following an injury or after a medical procedure. Bleeding can also occur internally into joints, muscles or internal organs. Spontaneous bleeding events may also occur. Complications in patients with hemophilia B include joint disease and hemarthrosis. Hemophilia B may be diagnosed when bleeding occurs in infancy or later in life for those with milder disease. There is a strong correlation between Factor IX levels and phenotypic expression of bleeding. Normal plasma levels of Factor IX range from 50% to 150%. The disease is classified based on reduced levels. Mild, moderate, and severe hemophilia B are characterized by Factor IX levels ranging from 6% up to 49%, 1% up to 5%, and < 1%, respectively. Besides Hemgenix, Factor IX products, both recombinant and plasma-derived, are used routinely to prevent bleeding or are given on demand to treat bleeding episodes associated with hemophilia B.

Clinical Efficacy

The efficacy of Hemgenix was evaluated in a prospective, open-label, single-dose, single-arm, multinational pivotal study called HOPE-B that involved 54 adult male patients with moderately severe or severe hemophilia B (Factor IX levels $\leq 2\%$).^{1,6-9} Patients prospectively completed a lead-in period of at least 6 month in which standard care routine Factor IX prophylaxis therapy was given.¹ This was followed by a single intravenous dose of 2×10^{13} genome copies/kg of body weight of Hemgenix. Patients were permitted to continue Factor IX prophylaxis during Months 0 to 6 after dosing, if needed, until Factor IX levels were adequate. The estimated mean annualized bleeding rate during Months 7 to 18 following Hemgenix treatment was 1.9 bleeds/year compared with 4.1 bleeds/year during the lead-in period (before Hemgenix administration).^{1,6-9} The HOPE-B trial is ongoing.¹ Other data are also available.¹⁰⁻¹²

Safety

Monitor patients during administration of Hemgenix and for at least 3 hours after the end of the infusion for infusion reactions. Closely monitor transaminase levels at least once per week for 3 months after Hemgenix administration to assess for the risk of potential hepatotoxicity. Consider corticosteroid treatment if elevations occur. Monitor for Factor IX activity and for Factor IX inhibitors.

Policy Statement

Prior Authorization is recommended for benefit coverage of Hemgenix. Approval is recommended for those who meet the Criteria and Dosing for the listed indication. Because of the specialized skills required for evaluation and diagnosis of patients treated with Hemgenix as well as the monitoring required for adverse events and long-term efficacy, approval requires Hemgenix to be prescribed by or in consultation with a physician who specializes in the condition being treated. For certain criteria, verification is required as noted by **[verification required by prescriber]**. All reviews (approvals and denials) will be forwarded to the Medical Director for evaluation. In the approval indication for Hemgenix, as appropriate, an asterisk (*) is noted next to the specified gender. In this context, the specified gender is defined as follows: men are defined as individuals with the biological traits of a man, regardless of the individual's gender identity or gender expression.

Documentation: Documentation is required where noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Hemgenix is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **Hemophilia B.** Approve a one-time per lifetime dose if the patient meets the following criteria (A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, and Q):
 - A) Patient is male^{*}; AND
 - B) Patient is greater than or equal to 18 years of age; AND
 - C) Patient has moderately severe or severe hemophilia B as evidence by a baseline (without Factor IX replacement therapy) Factor IX level of $\leq 2\%$ of normal **[documentation required]**; AND
 - D) Patient meets one of the following (i, ii, or iii):
 - i. Patient meets both of the following (a and b):
 - a) Patient has been receiving routine prophylaxis with Factor IX therapy continuously for at least 2 months **[documentation required]**; AND
 - b) According to the prescribing physician, the patient has a history of use of Factor IX therapy for at least 150 exposure days; OR
 - ii. Patient meets both of the following (a and b):
 - a) Patient has a history of life-threatening hemorrhage; AND
 - b) On-demand use of Factor IX therapy was required for this life-threatening hemorrhage; OR
 - iii. Patient meets both of the following (a and b):
 - a) Patient has a history of repeated, serious spontaneous bleeding episodes; AND
 - b) On-demand use of Factor IX therapy was required for these serious spontaneous bleeding episodes; AND
 - E) Patient meets all of the following criteria (i, ii, and iii) **[documentation required]**:
 - i. Factor IX inhibitor titer testing has been performed within 30 days before receipt of Hemgenix **[documentation required]**; AND
 - ii. Patient does not currently have an inhibitor to Factor IX **[documentation required]**; AND
 - iii. Patient does not have a history of Factor IX inhibitors **[documentation required]**; AND
 - F) Prescriber attests that prophylactic therapy with Factor IX will not be given after Hemgenix administration once adequate Factor IX levels have been achieved; AND
Note: Use of episodic Factor IX therapy is acceptable for the treatment of bleeds and for surgery/procedures if needed as determined by the hemophilia specialist physician.
 - G) Patient has not received Hemgenix in the past **[verification required by prescriber]**; AND
Note: Verify through claims history that the patient has not previously received Hemgenix AND, if no claim for Hemgenix is present, the prescriber must attest that the patient has not previously received Hemgenix.
 - H) Patient must meet both of the following (i and ii):
 - i. Patient does not have an active infection with hepatitis B virus or hepatitis C virus **[documentation required]**; AND
 - ii. Patient is not currently receiving antiviral therapy for a prior hepatitis B virus or C virus exposure **[documentation required]**; AND

- I) Patient does not have uncontrolled human immunodeficiency virus **[documentation required]**; AND
Note: A patient testing positive for human immunodeficiency virus can still qualify for Hemgenix if controlled on antiviral therapy with CD4+ counts $\geq 200/\mu\text{L}$ or by a viral load of ≤ 200 copies/mL.
- J) Patient has undergone a liver health assessment within the last 30 days and meets all of the following (i, ii, iii, and iv):
- i. Alanine aminotransferase is ≤ 2 times the upper limit of normal **[documentation required]**; AND
 - ii. Aspartate aminotransferase is ≤ 2 times the upper limit of normal **[documentation required]**; AND
 - iii. Total bilirubin levels are ≤ 2 times the upper limit of normal **[documentation required]**; AND
 - iv. Alkaline phosphatase levels are ≤ 2 times the upper limit of normal **[documentation required]**; AND
- K) Patient does not have evidence of advanced liver impairment and/or advanced fibrosis **[documentation required]**; AND
Note: For example, liver elastography (e.g., ≥ 9 kPa) suggestive of or equal to METAVIR Stage 3 disease.
- L) Within the last 30 days, platelet counts were evaluated and were $\geq 50 \times 10^9/\text{L}$ **[documentation required]**; AND
- M) Patient has adequate renal function as defined by meeting both of the following (i and ii):
- i. Patient has an estimate creatinine clearance ≥ 30 mL/min **[documentation required]**; AND
 - ii. Creatinine levels are ≤ 2 times the upper limit of normal **[documentation required]**; AND
- N) Physician attests that the patient does not have another coagulation disorder, besides hemophilia B; AND
- O) Following Hemgenix infusion, the physician attests that the following will be performed (i, ii, and iii):
- i. Patient meets both of the following (a and b):
 - a) Liver enzyme testing to monitor for liver enzyme elevations will be done at least weekly for the first 3 months and periodically thereafter; AND
 - b) Implementing a course of corticosteroids will be considered if the patient experiences clinically relevant increases in alanine aminotransferase levels; AND
 - ii. Patient will undergo monitoring for Factor IX activity at least weekly for the first 3 months and periodically thereafter; AND
 - iii. Patients with preexisting risk factors for hepatocellular carcinoma will receive abdominal ultrasound screenings and be monitored at least annually with alpha fetoprotein elevations in the 5 years following receipt of Hemgenix; AND
Note: Risk factors include a patient with prior history of hepatitis B and/or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, and advanced age.
- P) Medication is prescribed by a physician who specializes in hemophilia; AND
- Q) If criteria A through P are met, approve one dose (kit) of Hemgenix to provide for a one time (per lifetime) dose of 2×10^{13} genome copies based on current body weight in kg (within the past 30 days) **[documentation required]** by intravenous infusion. Table 1 provides the kit size and the National Drug Codes (NDCs).

* Refer to the Policy Statement.

Dosing. The recommended dose of Hemgenix is a single one time (per lifetime) intravenous infusion of 2×10^{13} genome copies based on current body weight in kg (within the past 30 days).

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Hemgenix is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

Table 1. Hemgenix Multi-Vial Kits.¹

Total Number of Vials per Kit	Patient Body Weight	Total Volume per Kit	NDC Number
10	46 to 50 kg	100	0053-0100-10
11	51 to 55 kg	110	0053-0110-11
12	56 to 60 kg	120	0053-0120-12
13	61 to 65 kg	130	0053-0130-13
14	66 to 70 kg	140	0053-0140-14
15	71 to 75 kg	150	0053-0150-15
16	76 to 80 kg	160	0053-0160-16
17	81 to 85 kg	170	0053-0170-17
18	86 to 90 kg	180	0053-0180-18
19	91 to 95 kg	190	0053-0190-19
20	96 to 100 kg	200	0053-0200-20
21	101 to 105 kg	210	0053-0210-21
22	106 to 110 kg	220	0053-0220-22
23	111 to 115 kg	230	0053-0230-23
24	116 to 120 kg	240	0053-0240-24
25	121 to 125 kg	250	0053-0250-25
26	126 to 130 kg	260	0053-0260-26
27	131 to 135 kg	270	0053-0270-27
28	136 to 140 kg	280	0053-0280-28
29	141 to 145 kg	290	0053-0290-29
30	146 to 150 kg	300	0053-0300-30
31	151 to 155 kg	310	0053-0310-31
32	156 to 160 kg	320	0053-0320-32
33	161 to 165 kg	330	0053-0330-33
34	166 to 170 kg	340	0053-0340-34
35	171 to 175 kg	350	0053-0350-35
36	176 to 180 kg	360	0053-0360-36
37	181 to 185 kg	370	0053-0370-37
38	186 to 190 kg	380	0053-0380-38
39	191 to 195 kg	390	0053-0390-39
40	196 to 200 kg	400	0053-0400-40
41	201 to 205 kg	410	0053-0410-41
42	206 to 210 kg	420	0053-0420-42
43	211 to 215 kg	430	0053-0430-43
44	216 to 220 kg	440	0053-0440-44
45	221 to 225 kg	450	0053-0450-45
46	226 to 230 kg	460	0053-0460-46
47	231 to 235 kg	470	0053-0470-47
48	236 to 240 kg	480	0053-0480-48

NDC – National Drug Code.

REFERENCES

1. Hemgenix® intravenous infusion [prescribing information]. King of Prussia, PA; Kankakee, IL; and Lexington, MA: CSL Behring and uniQure; November 2022.
2. National Hemophilia Foundation. Hemophilia B. An overview of symptoms, genetics, and treatments to help you understand hemophilia B. Available at: <https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-b>. Accessed on January 11, 2023.
3. Sidonio RF, Malec L. Hemophilia (Factor IX deficiency). *Hematol Oncol Clin N Am*. 2021;35:1143-1155.
4. Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. *Lancet*. 2021;397:630-640.
5. Croteau SE. Hemophilia A/B. *Hematol Oncol Clin N Am*. 2022;36:797-812.
6. Hemgenix™ Dossier. CSL Behring. December 2022.
7. Pipe S, Leebeek FWG, Recht M, et al (poster 2139). Durability of bleeding protection and factor IX activity levels are demonstrated in individuals with and without adeno-associated virus serotype 5 neutralizing antibodies (titers < 1:700) with comparable safety in the Phase 3 HOPE-B clinical trial of etranacogene dezaparvovec gene therapy for hemophilia B. Presented at: the American Society of Hematology (ASH) 64th Annual Meeting and Exposition; New Orleans, LA; December 10-13, 2022. Available at: <https://ash.confex.com/ash/2022/webprogram/Paper166745.html>. Accessed on December 31, 2022.
8. Pipe S, Leebeek FWG, Recht M, et al (poster 2141). Adults with severe or moderately severe hemophilia B receiving etranacogene dezaparvovec in the HOPE-B Phase 3 clinical trial continue to experience a stable increase in mean factor IX activity levels and durable hemostatic protection after 24 months' follow-up. Presented at: the American Society of Hematology (ASH) 64th Annual Meeting and Exposition; New Orleans, LA; December 10-13, 2022. Available at: <https://ash.confex.com/ash/2022/webprogram/Paper166135.html>. Accessed on December 31, 2022.
9. Miesbach WA, Recht M, Key NS, et al. Durability of Factor IX activity and bleeding rate in people with severe or moderately severe hemophilia B after 5 years of follow-up in the Phase 1/2 study of AMT-060, and after 3 years of follow-up in the Phase 2b and 2 years of follow-up in the Phase 3 studies of etranacogene dezaparvovec (AMT-061). Presented at: the American Society of Hematology (ASH) 64th Annual Meeting and Exposition; New Orleans, LA; December 10-13, 2022. Available at: <https://ash.confex.com/ash/2022/webprogram/Paper166810.html>. Accessed on December 31, 2022.
10. Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b); normal/near normal FIX activity and bleed cessation in hemophilia B. *Blood*. 2019;3(21):3241-3247.
11. Von Drygalski A, Gomez E, Giermasz A, et al. Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. *Blood Adv*. 2022 Dec 9. [Online ahead of print].
12. Shah J, Kim H, Sivamurthy K, et al. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. *Curr Med Res Opin*. 2022 Oct 25. [Online ahead of print].